scispace - formally typeset
D

Dean F. Bajorin

Researcher at Memorial Sloan Kettering Cancer Center

Publications -  553
Citations -  38878

Dean F. Bajorin is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Bladder cancer & Cancer. The author has an hindex of 86, co-authored 506 publications receiving 31799 citations. Previous affiliations of Dean F. Bajorin include Memorial Hospital of South Bend & University of Ulsan.

Papers
More filters
Journal ArticleDOI

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

TL;DR: Treatment with atezolizumab resulted in a significantly improved RECIST v1.1 response rate, compared with a historical control overall response rate of 10%, and Exploratory analyses showed The Cancer Genome Atlas (TCGA) subtypes and mutation load to be independently predictive for response to atezolediazepine.
Journal ArticleDOI

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Robert M. Samstein, +84 more
- 14 Jan 2019 - 
TL;DR: Analysis of advanced cancer patients treated with immune-checkpoint inhibitors shows that tumor mutational burden, as assessed by targeted next-generation sequencing, predicts survival after immunotherapy across multiple cancer types.
Journal ArticleDOI

Comprehensive molecular characterization of urothelial bladder carcinoma

John N. Weinstein, +296 more
- 01 Jan 2014 - 
TL;DR: Ch Chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any other common cancer studied so far, indicating the future possibility of targeted therapy for chromatin abnormalities.
Journal ArticleDOI

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

TL;DR: Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer.